Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Adenocor 3 mg/ml Solution for injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. Clear, colourless solution. |
Each vial contains 6 mg of adenosine per 2 ml (3 mg/ml).
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Adenosine is a purine nucleoside which is present in all cells of the body. Animal pharmacology studies have in several species shown that adenosine has a negative dromotropic effect on the atrioventricular (AV) node. |
| List of Excipients |
|---|
|
Sodium chloride |
Clear, type I glass vials with chlorobutyl rubber closures secured with aluminium caps. Packs of 6 vials in plastic trays in cardboard cartons.
Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
PL 04425/0159
Date of first authorisation: 01 September 2010
| Drug | Countries | |
|---|---|---|
| ADENOCOR | Estonia, Spain, Ireland, Lithuania, Netherlands, New Zealand, Poland, Singapore, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.